• Go to
  • Go to navigation
  • Info about avalibility
Logo ITK Go to homepage
Select Language
  • Polski
  • Angielski
  • Hiszpański
  • Rosyjski
  • Niemiecki
Logo ITK Go to homepage
  • Stem cells

    Therapeutic Product of Advanced Therapy

    Mesenchymal stem cells

  • About Institute

    What are we?

    Diseases treated

    Our team

    Walk on Institute

    Institute at conferences

  • For Patient

    Amytotrophic lateral sclerosis (ALS)

    Secondary-progressive multiple sclerosis (SPMS)

    Rare neurogenerative diseases

    Self-help book for patients

    FAQ

  • For Doctors
  • News

    Webinar: Mesenchymal stem cells - current therapeutic trend

    We confirm efficacy of intrathecal injection of Wharton’s jelly-derived mesenchymal stem cells!

    ITK researchers validated the international Amyotrophic Lateral Sclerosis Functional Rating Scale

    Unproven cell-based therapies – what are they? ITK’s position statement

    We confirm safety of intrathecal injection of Wharton’s jelly-derived mesenchymal stem cells!

  • Contact with ITK / Roadmap
  • Home
  • Stem cells
    • Therapeutic Product of Advanced Therapy
    • Mesenchymal stem cells
  • About Institute
    • What are we?
    • Diseases treated
      • Amytotrophic lateral sclerosis ALS
      • Secondary-progressive multiple sclerosis (SPMS)
      • Rare neurodegenerative diseases
    • Our team
    • Walk on Institute
    • Institute at conferences
  • For Patient
    • Amytotrophic lateral sclerosis (ALS)
      • On the Therapy
      • Initial qualification for the Therapy
      • Final qualification and the start of the Therapy
      • The Institute's research program
      • Documents for download
      • Pricelist
    • Secondary-progressive multiple sclerosis (SPMS)
      • On the Therapy
      • Initial qualification for the Therapy
      • Final qualification and the start of the Therapy
      • The Institute's research program
      • Documents for download
      • Pricelist
    • Rare neurogenerative diseases
      • On the Therapy
      • Initial qualification for the Therapy
      • Final qualification and the start of the Therapy
      • The Institute's research program
      • Documents for download
      • Pricelist
    • Self-help book for patients
    • FAQ
  • For Doctors
  • News
    • Webinar: Mesenchymal stem cells - current therapeutic trend
    • We confirm efficacy of intrathecal injection of Wharton’s jelly-derived mesenchymal stem cells!
    • ITK researchers validated the international Amyotrophic Lateral Sclerosis Functional Rating Scale
    • Unproven cell-based therapies – what are they? ITK’s position statement
    • We confirm safety of intrathecal injection of Wharton’s jelly-derived mesenchymal stem cells!
  • Contact with ITK / Roadmap
  • Privacy policy
  • Availability
Our partners
  • PBKM.pl
  • UWM

Contact us

  • ulica Warszawska 30,
    Budynek nr 7
    10-082 Olsztyn
  • rejestracja@itkmed.pl
  • +48 517 868 949
  • +48 895 245 656

Go to

  • Contact
  • Privacy Policy
  • Site map
  • Policy for processing personal data
Copyright © 2018 Polski Bank Komórek Macierzystych. All rights reserved.
Created by Squiz
Używamy plików cookies, aby ułatwić Ci korzystanie z naszego serwisu oraz do celów statystycznych. Jeśli nie blokujesz tych plików, to zgadzasz się na ich użycie oraz zapisanie w pamięci urządzenia. Pamiętaj, że możesz samodzielnie zarządzać cookies, zmieniając ustawienia przeglądarki. Więcej informacji w naszej Privacy policy Akceptuję Zamknij okno